Ibandronic acid (Bondronat) for the treatment of hypercalcaemia and bony metastases. Australian Prescriber review

From Australian Prescriber: Ibandronic acid Bondronat (Hospira) vials containing 6 mg/6 mL Approved indications: hypercalcaemia, bony metastases of breast cancer Australian Medicines Handbook section 10.3.1 Bisphosphonates can reduce the hypercalcaemia of malignant disease by inhibiting the resorption of bone. Clodronate, pamidronate and zoledronic acid are already available for this indication. They are now

Atrial fibrillation and bisphosphonates: FDA Medwatch update

FDA issued an update to the Agency’s review of safety data regarding the potential increased risk of atrial fibrillation in patients treated with a bisphosphonate drug. Bisphosphonates marketed as Alendronate (Fosamax, Fosamax Plus D) Etidronate (Didronel) Ibandronate (Boniva) Pamidronate (Aredia) Risedronate (Actonel, Actonel W/Calcium) Tiludronate (Skelid) Zoledronic acid (Reclast, Zometa) Bisphosphonates are a class of […]